Home Companies Catalysts Deep Dives
Talvey talquetamab APPROVED
Drug Profile
ModalityBispecific
RouteSC
Therapy AreaOncology
Launch2023-08-09
US LOE2035-08-09
Peak Sales Est$2100M
Formulations[{"id":"talvey-sc","route":"SC","setting":"OFFICE","frequency":"Weekly to biweekly","is_primary":tru
Companies
GMAB (ROYALTY)0%
JNJ (LICENSEE)0%
Mechanism: GPRC5DxCD3 bispecific
Expert: Bispecific T-cell engager binding GPRC5D on myeloma cells and CD3 on T-cells, providing alternative target to BCMA.
Everyday: A protein that helps immune cells find and destroy myeloma cells using a different target.
Targets: ["GPRC5D","CD3"]
Revenue History
PeriodRevenue ($M)
2025$800M
2024$227M
Programs (1)
IndicationStageKey StudyRegional Status
R/R MMAPPROVEDMonumenTAL-1[{"stage":"APPROVED","region":"US","approval_date":"2023-08-09"},{"stage":"APPRO
Notes
First GPRC5D-targeting bispecific for R/R MM. Alternative target to BCMA for patients who failed BCMA-directed therapy. Genmab receives royalties from J&J.
Data from Supabase · Updated 2026-03-24